Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

Core Insights - Tevogen Bio Holdings Inc. has been recognized by Yale University for its commitment to health equity and the leadership of its Founder and CEO, Dr. Ryan Saadi [2] - The company operates with a lean, capital-efficient business model, fully owning its core intellectual property to minimize costs and complexity in developing CD8+ T cell therapies [3] - Dr. Saadi emphasized that affordability and accessibility are foundational to Tevogen's operations, achieving significant milestones with lower capital expenditure compared to industry norms [4] Business Model and Strategy - Tevogen's business model is designed to withstand market pressures through a capital-efficient structure, focusing on off-the-shelf, genetically unmodified therapies [3] - The company has avoided the typical billion-dollar burn rate seen in the industry, maintaining a lean cash run rate while preserving equity [4] - Tevogen aims to deliver innovative therapies that not only improve patient outcomes but also achieve commercial success at a lower cost [4] Recognition and Impact - The recognition from Yale highlights the impact of Tevogen's mission on making healthcare more affordable and accessible [2] - Dr. Saadi's vision is acknowledged as a significant contribution to the healthcare landscape, reinforcing the company's commitment to health equity [2][4]